nach oben

Erschienen in:

29.03.2019 | Migräne | Fortbildung

Einsatz in der Neuroimmunologie, Onkologie und Schmerztherapie

Was kann die Antikörpertherapie in der Neurologie?

verfasst von: Prof. Dr. med. Dr. rer. nat. Sven G. Meuth, Dr. med. Marc Pawlitzki

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Bedeutung antigengerichteter Therapien mittels Antikörper in der Neurologie begrenzt sich seit mehreren Jahren nicht nur auf typische Autoimmunerkrankungen wie die Multiple Sklerose, sondern wird auch zur Unterbrechung pathophysiologischer Prozesse wie der Schmerzweiterleitung intensiv erforscht. Damit ergeben sich immer weitere Behandlungsfelder. Neben den damit verbundenen neuen Therapieoptionen ist jedoch auch ein zunehmendes Wissen über den Wirkmechanismus seitens des Behandlers erforderlich, um potenzielle Nebenwirkungen und Komplikationen zu (er-)kennen, darüber aufzuklären und entsprechende Begleituntersuchungen einzuleiten.

Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356(6364):63–6. doi: https://doi.org/10.1038/356063a0.PubMedCrossRef

Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60(4):577–84.PubMedCrossRef

Sehr T, Proschmann U, Thomas K, Marggraf M, Straube E, Reichmann H et al. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. J Neuroinflammation 2016; 13(1):164. doi: https://doi.org/10.1186/s12974-016-0635-2.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9):899–910. doi: https://doi.org/10.1056/NEJMoa044397.PubMedCrossRef

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354(9):911–23. doi: https://doi.org/10.1056/NEJMoa044396.PubMedCrossRef

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366(20):1870–80. doi: https://doi.org/10.1056/NEJMoa1107829.PubMedCrossRef

Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification. Neurology 2017; 88(12):1197–205. doi: https://doi.org/10.1212/WNL.0000000000003739.PubMedCrossRef

Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76(6):802–12. doi: https://doi.org/10.1002/ana.24286.PubMedCrossRef

Ho P-R, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies. The Lancet Neurology 2017; 16(11):925–33. doi: {rs 10.1016/S1474-4422(17)30282-X DOI}.PubMedCrossRef

10.

McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016; 87(2):117–25. doi: https://doi.org/10.1136/jnnp-2015-311100.PubMed

11.

Baldassari LE, Jones SE, Clifford DB, Fox RJ. Progressive multifocal leukoencephalopathy with extended natalizumab dosing. Neurol Clin Pract 2018; 8(3):e12–e14. doi: https://doi.org/10.1212/CPJ.0000000000000457.PubMedPubMedCentralCrossRef

12.

Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87(8):885–9. doi: https://doi.org/10.1136/jnnp-2015-312940.PubMedCrossRef

13.

Kobeleva X, Wegner F, Brunotte I, Dadak M, Dengler R, Stangel M. Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab. J Neuroinflammation 2014; 11:19. doi: https://doi.org/10.1186/1742-2094-11-19.PubMedPubMedCentralCrossRef

14.

Mulero P, Auger C, Parolin L, Fonseca E, Requena M, Rio J et al. Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab. Mult Scler 2018; 24(3):358–60. doi: https://doi.org/10.1177/1352458517711569.PubMedCrossRef

15.

Pawlitzki M, Teuber J, Campe C, Wagner M, Schuart C, Paul F et al. VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab. Neurol Neuroimmunol Neuroinflamm 2018; 5(5):e475. doi: https://doi.org/10.1212/NXI.0000000000000475.PubMedPubMedCentralCrossRef

16.

Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 2012; 142(1):25–30. doi: https://doi.org/10.1016/j.clim.2011.04.006.PubMedCrossRef

17.

Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015; 8(1):31–45. doi: https://doi.org/10.1177/1756285614563522.PubMedPubMedCentralCrossRef

18.

Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci 2015; 16(7):16414–39. doi: https://doi.org/10.3390/ijms160716414.PubMedPubMedCentralCrossRef

19.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. The Lancet 2012; 380(9856):1819–28. doi: https://doi.org/10.1016/S0140-6736(12)61769-3.CrossRef

20.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. The Lancet 2012; 380(9856):1829–39. doi: https://doi.org/10.1016/S0140-6736(12)61768-1.CrossRef

21.

Sanofigenzyme. Verfügbar unter: https://news.sanofigenzyme.com/press-release/sanofi-presents-8-year-data-lemtrada-alemtuzumab.

22.

Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M et al. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. J Neurol 2018. doi: https://doi.org/10.1007/s00415-018-9117-z.

23.

Guarnera C, Bramanti P, Mazzon E. Alemtuzumab: A review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag 2017; 13:871–9. doi: https://doi.org/10.2147/TCRM.S134398.PubMedPubMedCentralCrossRef

24.

Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf 2018; 17(7):709–17. doi: https://doi.org/10.1080/14740338.2018.1483330.PubMedCrossRef

25.

Pappolla A, Midaglia L, Boix Rodríguez CP, Puig AA, Lung M, Camps IR et al. Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis. Neurology 2018. doi: https://doi.org/10.1212/WNL.0000000000006801.

26.

Canham LJW, Manara A, Fawcett J, Rolinski M, Mortimer A, Inglis KEA et al. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis. Mult Scler Relat Disord 2018; 24:38–41. doi: https://doi.org/10.1016/j.msard.2018.05.014.PubMedCrossRef

27.

Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D et al. Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells. Neurology 2018; 91(24):e2233–e2237. doi: https://doi.org/10.1212/WNL.0000000000006648.PubMedPubMedCentralCrossRef

28.

Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology 2016; 87(20):2074–81. doi: https://doi.org/10.1212/WNL.0000000000003331.PubMedPubMedCentralCrossRef

29.

Flon P de, Gunnarsson M, Laurell K, Söderström L, Birgander R, Lindqvist T et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology 2016; 87(2):141–7. doi: https://doi.org/10.1212/WNL.0000000000002832.PubMedCrossRef

30.

Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76(15):1310–5. doi: https://doi.org/10.1212/WNL.0b013e3182152881.PubMedCrossRef

31.

Ellwardt E, Ellwardt L, Bittner S, Zipp F. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflamm 2018; 5(4):e463. doi: https://doi.org/10.1212/NXI.0000000000000463.PubMedPubMedCentralCrossRef

32.

Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66(4):460–71. doi: https://doi.org/10.1002/ana.21867.PubMedCrossRef

33.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376(3):221–34. doi: https://doi.org/10.1056/NEJMoa1601277.PubMedCrossRef

34.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376(3):209–20. doi: https://doi.org/10.1056/NEJMoa1606468.PubMedCrossRef

35.

Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010; 51(6):983–94. doi: https://doi.org/10.3109/10428191003717746.PubMedCrossRef

36.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology 2018; 90(20):e1805–e1814. doi: https://doi.org/10.1212/WNL.0000000000005516.PubMedPubMedCentralCrossRef

37.

Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113(20):4834–40. doi: https://doi.org/10.1182/blood-2008-10-186999.PubMedPubMedCentralCrossRef

38.

Stellmann J-P, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K et al. Immunotherapies in neuromyelitis optica spectrum disorder: Efficacy and predictors of response. J Neurol Neurosurg Psychiatry 2017; 88(8):639–47. doi: https://doi.org/10.1136/jnnp-2017-315603.PubMedPubMedCentralCrossRef

39.

Damato V, Evoli A, Iorio R. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol 2016; 73(11):1342–8. doi: https://doi.org/10.1001/jamaneurol.2016.1637.PubMedCrossRef

40.

Cabre P, Mejdoubi M, Jeannin S, Merle H, Plumelle Y, Cavillon G et al. Treatment of neuromyelitis optica with rituximab: A 2-year prospective multicenter study. J Neurol 2018; 265(4):917–25. doi: https://doi.org/10.1007/s00415-018-8771-5.PubMedCrossRef

41.

Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: A randomized clinical trial. J Neurol 2017; 264(9):2003–9. doi: https://doi.org/10.1007/s00415-017-8590-0.PubMedCrossRef

42.

Ringelstein M, Ayzenberg I, Harmel J, Lauenstein A-S, Lensch E, Stögbauer F et al. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol 2015; 72(7):756–63. doi: https://doi.org/10.1001/jamaneurol.2015.0533.PubMedCrossRef

43.

Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study. Neurology 2014; 82(15):1302–6. doi: https://doi.org/10.1212/WNL.0000000000000317.PubMedPubMedCentralCrossRef

44.

Hayakawa M, Izumi K, Higashida-Konishi M, Ushikubo M, Tsukamoto M, Akiya K et al. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: A case-based review. Rheumatol Int 2018. doi: https://doi.org/10.1007/s00296-018-4175-1.

45.

Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. The Lancet Neurology 2013; 12(6):554–62. doi: https://doi.org/10.1016/S1474-4422(13)70076-0.PubMedCrossRef

46.

Alexion Pressemitteilung. Verfügbar unter: https://news.alexionpharma.com/press-release/product-news/alexion-announces-successful-phase-3-prevent-study-soliris-eculizumab-pat.

47.

Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve 2017; 56(2):185–96. doi: https://doi.org/10.1002/mus.25597.PubMedCrossRef

48.

Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study. The Lancet Neurology 2017; 16(12):976–86. doi: https://doi.org/10.1016/S1474-4422(17)30369-1.PubMedCrossRef

49.

Gilhus NE. Eculizumab: A treatment option for myasthenia gravis? The Lancet Neurology 2017; 16(12):947–8. doi: https://doi.org/10.1016/S1474-4422(17)30363-0.PubMedCrossRef

50.

Benamu E, Montoya JG. Infections associated with the use of eculizumab: Recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016; 29(4):319–29. doi: https://doi.org/10.1097/QCO.0000000000000279.PubMedCrossRef

51.

Schubert J, Brämer D, Huttner HB, Gerner ST, Fuhrer H, Melzer N et al. Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol Neuroinflamm 2019; 6(1):e514. doi: https://doi.org/10.1212/NXI.0000000000000514.PubMedCrossRef

52.

Melzer N, Meuth SG, Wiendl H. Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. J Neurol 2013; 260(5):1215–33. doi: https://doi.org/10.1007/s00415-012-6657-5.PubMedCrossRef

53.

Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3(6):401–10. doi: https://doi.org/10.1038/nrc1093.PubMedCrossRef

54.

Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R et al. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. Eur J Cancer 2017; 75:245–58. doi: https://doi.org/10.1016/j.ejca.2017.01.026.PubMedCrossRef

55.

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27(28):4733–40. doi: https://doi.org/10.1200/JCO.2008.19.8721.PubMedCrossRef

56.

Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 2017; 377(20):1954–63. doi: https://doi.org/10.1056/NEJMoa1707358.PubMedCrossRef

57.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370(8):699–708. doi: https://doi.org/10.1056/NEJMoa1308573.PubMedPubMedCentralCrossRef

58.

Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 2015; 11(9):504–14. doi: https://doi.org/10.1038/nrneurol.2015.139.PubMedPubMedCentralCrossRef

59.

Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. The Lancet Oncology 2016; 17(12):e542–e551. doi: https://doi.org/10.1016/S1470-2045(16)30406-5.PubMedPubMedCentralCrossRef

60.

Duruisseaux M, Lize-Dufranc C, Badoual C, Bibeau F. Biomarqueurs prédictifs de l’efficacité des inhibiteurs de checkpoint immunitaire dans le traitement des cancers. Ann Pathol 2017; 37(1):46–54. doi: https://doi.org/10.1016/j.annpat.2016.12.016.PubMedCrossRef

61.

Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: The game is not over yet. Oncotarget 2017; 8(53):91779–94. doi: https://doi.org/10.18632/oncotarget.21586.PubMedPubMedCentralCrossRef

62.

Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol 2016; 2(10):1346–53. doi: https://doi.org/10.1001/jamaoncol.2016.1051.PubMedCrossRef

63.

Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44:51–60. doi: https://doi.org/10.1016/j.ctrv.2016.02.001.PubMedCrossRef

64.

Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38(6):1026–37. doi: https://doi.org/10.1177/0333102418759786.PubMedCrossRef

65.

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017; 377(22):2123–32. doi: https://doi.org/10.1056/NEJMoa1705848.PubMedCrossRef

66.

Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. The Lancet 2018; 392(10161):2280–7. doi: https://doi.org/10.1016/S0140-6736(18)32534-0.CrossRef

67.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91(24):e2211–e2221. doi: https://doi.org/10.1212/WNL.0000000000006640.PubMedPubMedCentralCrossRef

68.

Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim B-K, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38(8):1442–54. doi: https://doi.org/10.1177/0333102418779543.PubMedCrossRef

69.

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 2018; 75(9):1080–8. doi: https://doi.org/10.1001/jamaneurol.2018.1212.PubMedPubMedCentralCrossRef

70.

Lamb YN. Galcanezumab: First Global Approval. Drugs 2018; 78(16):1769–75. doi: https://doi.org/10.1007/s40265-018-1002-7.PubMedCrossRef

71.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med 2017; 377(22):2113–22. doi: https://doi.org/10.1056/NEJMoa1709038.PubMedCrossRef

72.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 2018; 319(19):1999–2008. doi: https://doi.org/10.1001/jama.2018.4853.PubMedCrossRef

73.

Kee Z, Kodji X, Brain SD. The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects. Front Physiol 2018; 9:1249. doi: https://doi.org/10.3389/fphys.2018.01249.PubMedPubMedCentralCrossRef

74.

Ohlsson L, Kronvall E, Stratton J, Edvinsson L. Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. J Headache Pain 2018; 19(1):66. doi: https://doi.org/10.1186/s10194-018-0905-8.PubMedPubMedCentralCrossRef

Titel: Einsatz in der Neuroimmunologie, Onkologie und Schmerztherapie
Was kann die Antikörpertherapie in der Neurologie?
verfasst von: Prof. Dr. med. Dr. rer. nat. Sven G. Meuth
Dr. med. Marc Pawlitzki
Publikationsdatum: 29.03.2019
Verlag: Springer Medizin
Schlagwörter: Migräne
Multiple Sklerose
Rituximab
Neuromyelitis-optica-Spektrum-Erkrankung
Rituximab
Natalizumab
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 2/2019
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-019-2169-9

Passend zum Thema

Service mit Mehrwert

Services in der MS-Therapie für Neurolog*innen und Betroffene

Diagnose und Therapie der MS können für Patient*innen und Neurolog*innen mit Herausforderungen einhergehen [1,2]. Mit umfangreichen Servicemaßnahmen klärt Biogen Ärztinnen und Ärzte über mögliche Therapieoptionen auf und unterstützt diese bei der Fortbildung sowie Betroffene im Alltag.

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Schöne neue (Daten-)Welt

Esketamin bei therapieresistenter Depression: „Schnelles Ansprechen ist der Clou“

Medikamentöse Therapie bei Schwindel: Was gibt es Neues?

Reanalyse zu Johanniskrautpräparat

Psychosen: Halluzination als Folge kindlicher Traumata

Schizophrenie: Verschlechtern unterschwellige Symptome die Prognose?

Passend zum Thema

Services in der MS-Therapie für Neurolog*innen und Betroffene